Fig. 1 · Structure

Documents & Downloads

Quarfloxin (CX-3543)

Cat. No. A12380 CAS 865311-47-3

rRNA biogenesis inhibitor

Quarfloxin (CX-3543) is a fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.

In Stock

Publications for Quarfloxin

8 publications citing this product

  1. Rocio Diaz Escarcega, .et al. , Cell Death Dis, 2026, Jun 18 PMID: 42310298
  2. Maria Sultan, .et al. , J Biomed Sci, 2025, Feb 5;32(1):15 PMID: 39905515
  3. Jing-Wei Liang, .et al. , Antioxidants (Basel), 2023, Dec 20;13(1):11 PMID: 38275631
  4. Maria Razzaq, .et al. , Arch Pharm Res, 2023, Jul;46(7):598-615 PMID: 37563335
  5. Janne J. M. van Schie, .et al. , Nat Commun, 2020, 11: 4287 PMID: 32855419
  6. Yue Sheng, .et al. , Blood, 2020, Aug 21 PMID: 32822452
  7. Hald øH, .et al. , Oncogene, 2018, Dec 12 PMID: 30542116
  8. Louise E. Kerry, .et al. , PLoS Negl Trop Dis, 2017, Mar; 11(3): e0005432 PMID: 28263991

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Quarfloxin (CX-3543) disrupts nucleolin–rDNA G-quadruplex interactions in cell-free assays. In A549 cells, it reduced pre-rRNA after 2 hours (reported IC50 1.8 μmol/L) without inhibiting the four assayed Pol II transcripts. These findings support inhibition of rRNA biogenesis under the tested conditions. [1]

The pre-rRNA response depends on model, dose and time: in IMR-32 cells, 150 nM quarfloxin did not significantly reduce 47S pre-rRNA at 24 hours, whereas 1500 nM did. Cellular viability effects should therefore not be treated as a direct measurement of Pol I inhibition. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Quarfloxin (CX-3543) Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of Quarfloxin (CX-3543) from 3 published references. In vitro models include human A549 lung carcinoma cells; human MYCN-amplified, TP53-wild-type IMR-32 neuroblastoma cells.

Quarfloxin (CX-3543) In Vitro Studies

Quarfloxin reduced neuroblastoma cell viability after 48 hours, with IC50 values ranging from 5.0 ± 2.2 nM in IMR-32 to 967.6 ± 178.8 nM in SK-N-FI (mean ± SD between two independent experiments). Potency varied substantially across models. [2]

Displacement of nucleolin from rDNA G-quadruplexes

Biochemical assay · Recombinant human nucleolin and rDNA-derived G-quadruplex oligonucleotides [1]

CX-3543 displaced nucleolin from multiple rDNA G-quadruplexes, with reported Ki values of 18–320 nmol/L among quantified complexes. Inhibition was not detected for the 11028NT complex. The 6534NT experiment included a scrambled-DNA binding control and a nucleolin–RNA-hairpin competition control; the latter interaction was retained.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Disruption of nucleolin–6534NT G-quadruplex complexKi 98 nmol/L[1]
Disruption of nucleolin–6960NT G-quadruplex complexKi 18 nmol/L[1]
Disruption of nucleolin–11028NT complexInhibition detection ND (not detected)[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3–30 μmol/L CX-3543 in competition assays
Exposure duration
30 min
Method
Competition with 5 nmol/L labeled rDNA G-quadruplex and 10 nmol/L nucleolin at ambient temperature; gel mobility shift.
Vehicle
Compound stock: 10% polyethylene glycol 300, 2% mannitol, 25 mmol/L phosphate buffer (pH 6); competition performed in the reported binding buffer.
Reported limits
No Ki uncertainty or replicate count specified in Table 1. The ±SEM table annotation belongs to nucleolin Kd, not CX-3543 Ki.
Methods and source locations

Compound reported in the paper: Quarfloxin (CX-3543); Compound label in the paper: CX-3543

Applies to quarfloxin/CX-3543 as reported by the authors; no salt conversion or current-lot validation.

Table 1 (p.7654), 6534NT/6960NT/11028NT rows; Methods: Interaction of nucleolin protein with rDNA G-quadruplexes and competition by CX-3543; SI Fig.S1

Disruption of nucleolin–6534NT G-quadruplex complex: Gel mobility-shift competition; Ki calculated using the Cheng–Prusoff equation, not a direct drug–DNA binding Kd. — Table 1 (p.7654), 6534NT/6960NT/11028NT rows; Methods: Interaction of nucleolin protein with rDNA G-quadruplexes and competition by CX-3543; SI Fig.S1

Disruption of nucleolin–6960NT G-quadruplex complex: Gel mobility-shift competition; Cheng–Prusoff calculation. — Table 1 (p.7654), 6534NT/6960NT/11028NT rows; Methods: Interaction of nucleolin protein with rDNA G-quadruplexes and competition by CX-3543; SI Fig.S1

Disruption of nucleolin–11028NT complex: Table 1; this is an exception to the quantified displacement results, not evidence of universal G4 displacement. — Table 1 (p.7654), 6534NT/6960NT/11028NT rows; Methods: Interaction of nucleolin protein with rDNA G-quadruplexes and competition by CX-3543; SI Fig.S1

Short-term pre-rRNA suppression in A549 cells

Cell-based study · Human A549 lung carcinoma cells [1]

Two-hour CX-3543 exposure reduced pre-rRNA dose-dependently (reported IC50 1.8 μmol/L), while the assayed bcl-2, c-myb, c-myc and k-ras mRNAs were not inhibited under these conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pre-rRNA abundance after 2 h exposureIC50 1.8 μmol/L[1]
bcl-2, c-myb, c-myc and k-ras mRNA abundanceTranscript selectivity No inhibitory effect reported[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.08–25 μmol/L
Exposure duration
2 h
Method
qRT-PCR of pre-rRNA and the four indicated mRNAs, relative to untreated cells.
Vehicle
CX-3543 stock in 10% polyethylene glycol 300, 2% mannitol and 25 mmol/L phosphate buffer (pH 6), diluted directly into growth medium.
Reported limits
Replicate number and error-bar definition for Fig.4C are not specified in its caption. Do not treat IC50 as a treatment dose.
Methods and source locations

Compound reported in the paper: Quarfloxin (CX-3543); Compound label in the paper: CX-3543

Applies to quarfloxin/CX-3543 as reported by the authors; no salt conversion or current-lot validation.

Fig.4C (p.7657); qRT-PCR Methods (p.7656); Results: CX-3543 selectively inhibits rRNA synthesis (p.7659)

Pre-rRNA abundance after 2 h exposure: qRT-PCR; value explicitly reported in Results, not estimated from the curve. — Fig.4C (p.7657); qRT-PCR Methods (p.7656); Results: CX-3543 selectively inhibits rRNA synthesis (p.7659)

bcl-2, c-myb, c-myc and k-ras mRNA abundance: qRT-PCR comparison of pre-rRNA with four Pol II transcripts; Fig.4C and associated Results. — Fig.4C (p.7657); qRT-PCR Methods (p.7656); Results: CX-3543 selectively inhibits rRNA synthesis (p.7659)

Neuroblastoma cell viability panel

Cell-based study · IMR-32, CHP-134, CHLA-15, BE(2)-C, Kelly, SK-N-AS and SK-N-FI human neuroblastoma cells [2]

Quarfloxin reduced Alamar blue viability across the panel, with substantial model-dependent potency differences. MYCN-amplified/TP53-wild-type IMR-32 and CHP-134 were more sensitive than MYCN-non-amplified/TP53-mutant SK-N-AS and SK-N-FI. Values are mean IC50 ± SD between two independent experiments, each with two biological replicates per concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IMR-32 Alamar blue viabilityIC50 (mean ± SD) 5.0 ± 2.2 nM[2]
CHP-134 Alamar blue viabilityIC50 (mean ± SD) 23.0 ± 14.7 nM[2]
CHLA-15 Alamar blue viabilityIC50 (mean ± SD) 54.0 ± 3.7 nM[2]
BE(2)-C Alamar blue viabilityIC50 (mean ± SD) 84.3 ± 5.0 nM[2]
Kelly Alamar blue viabilityIC50 (mean ± SD) 150.1 ± 33.7 nM[2]
SK-N-AS Alamar blue viabilityIC50 (mean ± SD) 965.2 ± 122.8 nM[2]
SK-N-FI Alamar blue viabilityIC50 (mean ± SD) 967.6 ± 178.8 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.001–10000 nM quarfloxin
Exposure duration
48 h drug exposure, followed by 2 h Alamar blue incubation
Method
Alamar blue fluorescence; vehicle-normalized viability.
Vehicle
DMSO; vehicle concentration never exceeded 0.1%.
Reported limits
No assumption that Alamar blue reduction alone distinguishes cytostasis from cell death.
Methods and source locations

Compound reported in the paper: Quarfloxin (CX-3543); Compound label in the paper: Quarfloxin

Applies to quarfloxin/CX-3543 as reported by the authors; no salt conversion or current-lot validation.

Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

IMR-32 Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

CHP-134 Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

CHLA-15 Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

BE(2)-C Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

Kelly Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

SK-N-AS Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

SK-N-FI Alamar blue viability: 48 h treatment followed by 2 h Alamar blue incubation; normalized to vehicle; log(inhibitor) versus normalized response, variable-slope fit. Two independent experiments with two biological replicates per concentration. — Fig.2a; Table 1 (p.2804); Methods: Chemicals, Cell culture, Viability assays

Dose-dependent pre-rRNA response in IMR-32 cells

Cell-based study · Human MYCN-amplified, TP53-wild-type IMR-32 neuroblastoma cells [2]

At 24 h, 150 nM quarfloxin did not significantly change 47S pre-rRNA relative to DMSO, whereas 1500 nM significantly reduced it. The low-dose null result limits attribution of all cytotoxic responses to measurable pre-rRNA suppression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
47S pre-rRNA at 150 nM quarfloxin for 24 hRelative pre-rRNA expression ns (not significant)[2]
47S pre-rRNA at 1500 nM quarfloxin for 24 hRelative pre-rRNA expression Decreased; ****p ≤ 0.0001[2]

Literature-Reported Treatment Conditions

Treatment concentration
150 nM and 1500 nM
Exposure duration
24 h
Method
RT-qPCR. Methods describe ddCT relative expression and normalization of rRNA transcripts using the geometric mean of all rRNA transcripts.
Vehicle
DMSO; vehicle concentration never exceeded 0.1%.
Reported limits
Fig.5 caption does not specify replicate number or the error-bar statistic. Relative RNA abundance is a proxy and does not directly measure polymerase catalytic activity.
Methods and source locations

Compound reported in the paper: Quarfloxin (CX-3543); Compound label in the paper: Quarfloxin

Applies to quarfloxin/CX-3543 as reported by the authors; no salt conversion or current-lot validation.

Fig.5b,c and caption; Results: Quarfloxin and CX-5461 reduce the expression of MycN and pre-rRNA (47S-rRNA); Methods: Chemicals and RT-qPCR

47S pre-rRNA at 150 nM quarfloxin for 24 h: RT-qPCR; Fig.5b, relative to DMSO vehicle. No exact fold change inferred from bars. — Fig.5b,c and caption; Results: Quarfloxin and CX-5461 reduce the expression of MycN and pre-rRNA (47S-rRNA); Methods: Chemicals and RT-qPCR

47S pre-rRNA at 1500 nM quarfloxin for 24 h: RT-qPCR; Fig.5c, relative to DMSO vehicle. No exact fold change inferred from bars. — Fig.5b,c and caption; Results: Quarfloxin and CX-5461 reduce the expression of MycN and pre-rRNA (47S-rRNA); Methods: Chemicals and RT-qPCR

Quarfloxin (CX-3543) In Vivo Studies

In nude mice bearing TS 543 glioma xenografts, intravenous CX-3543 at 12.5 mg/kg once daily on a 5-day/week schedule suppressed tumor growth after ATRX knockdown. The same regimen had no appreciable growth effect in ATRX-intact TS 543 tumors, indicating a model-dependent response. [3]

ATRX-intact TS 543 xenograft growth

Animal study · Nude mice bearing hind-flank TS 543 human glioma stem-cell xenografts with intact ATRX [3]

CX-3543 did not appreciably alter growth of ATRX-intact TS 543 xenografts compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume over time versus vehicleTumor growth comparison P = 0.1956[3]

Conditions shared by the study groups

Route
Intravenous
Frequency
Once daily, 5 days/week
Treatment course
For growth comparisons, all animals in a cohort were sacrificed when the first mouse reached the 2000 mm³ tumor threshold; no fixed course stated.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CX-3543 versus vehicle
12.5 mg/kg
Vehicle control; n = 3 mice per groupCX-3543 did not appreciably alter growth of ATRX-intact TS 543 xenografts compared with vehicle.[3]
CX-3543 versus vehicle
Model: Nude mice bearing hind-flank TS 543 human glioma stem-cell xenografts with intact ATRX
Reported limits: Vehicle composition and fixed duration not specified in inspected main-text methods. No strain beyond nude mice, sex or age assigned.
Methods and source locations

Compound reported in the paper: Quarfloxin (CX-3543); Compound label in the paper: CX-3543

Applies to quarfloxin/CX-3543 as reported by the authors; no salt conversion or current-lot validation.

Fig.8a and caption; Results: ATRX loss enhances sensitivity to G4 stabilization in vivo; Methods: Study design, Xenograft experiments, Statistics

Tumor volume over time versus vehicle: Caliper tumor volume (l × w²)/2; two-way ANOVA; n = 3 mice per group. Figure curves viewed; exact volumes not digitized. — Fig.8a and caption; Results: ATRX loss enhances sensitivity to G4 stabilization in vivo; Methods: Study design, Xenograft experiments, Statistics

CX-3543 versus vehicle · Fig.8a and caption; Results: ATRX loss enhances sensitivity to G4 stabilization in vivo; Methods: Study design, Xenograft experiments, Statistics

ATRX-knockdown TS 543 xenograft growth

Animal study · Nude mice bearing hind-flank TS 543 human glioma stem-cell xenografts with ATRX knockdown (sh590) [3]

CX-3543 suppressed growth of TS 543-sh590 xenografts compared with vehicle in the ATRX-knockdown model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume over time versus vehicleTumor growth comparison P < 0.0001[3]

Conditions shared by the study groups

Route
Intravenous
Frequency
Once daily, 5 days/week
Treatment course
For growth comparisons, all animals in a cohort were sacrificed when the first mouse reached the 2000 mm³ tumor threshold; no fixed course stated.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CX-3543 versus vehicle
12.5 mg/kg
Vehicle control; n = 5 mice per groupCX-3543 suppressed growth of TS 543-sh590 xenografts compared with vehicle in the ATRX-knockdown model.[3]
CX-3543 versus vehicle
Model: Nude mice bearing hind-flank TS 543 human glioma stem-cell xenografts with ATRX knockdown (sh590)
Reported limits: Vehicle composition and fixed duration not specified in inspected main-text methods. No strain beyond nude mice, sex or age assigned.
Methods and source locations

Compound reported in the paper: Quarfloxin (CX-3543); Compound label in the paper: CX-3543

Applies to quarfloxin/CX-3543 as reported by the authors; no salt conversion or current-lot validation.

Fig.8c and caption; Results: ATRX loss enhances sensitivity to G4 stabilization in vivo; Methods: Study design, Xenograft experiments, Statistics

Tumor volume over time versus vehicle: Caliper tumor volume (l × w²)/2; two-way ANOVA; n = 5 mice per group. Figure curves viewed; exact volumes not digitized. — Fig.8c and caption; Results: ATRX loss enhances sensitivity to G4 stabilization in vivo; Methods: Study design, Xenograft experiments, Statistics

CX-3543 versus vehicle · Fig.8c and caption; Results: ATRX loss enhances sensitivity to G4 stabilization in vivo; Methods: Study design, Xenograft experiments, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 865311-47-3
Applications rRNA biogenesis inhibitor
Formula C35H33FN6O3
Molecular Weight 604.67
Synonyms CX 3543; Quarfloxacin
SMILES
CN1CCC[C@H]1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 18 mg/mL (35.57 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+dd H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Quarfloxin (CX-3543) Research References

  1. [1] Drygin D, Siddiqui-Jain A, O'Brien S, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer research (2009). PMID: 19738048 DOI: 10.1158/0008-5472.can-09-1304 Source material
  2. [2] Hald ØH, Olsen L, Gallo-Oller G, et al. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma. Oncogene (2019). PMID: 30542116 DOI: 10.1038/s41388-018-0611-7 Source material
  3. [3] Wang Y, Yang J, Wild AT, et al. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nature communications (2019). PMID: 30808951 DOI: 10.1038/s41467-019-08905-8 Source material

Publications

8 publications citing this product

  1. Rocio Diaz Escarcega, .et al. , Cell Death Dis, 2026, Jun 18 PMID: 42310298
  2. Maria Sultan, .et al. , J Biomed Sci, 2025, Feb 5;32(1):15 PMID: 39905515
  3. Jing-Wei Liang, .et al. , Antioxidants (Basel), 2023, Dec 20;13(1):11 PMID: 38275631
  4. Maria Razzaq, .et al. , Arch Pharm Res, 2023, Jul;46(7):598-615 PMID: 37563335
  5. Janne J. M. van Schie, .et al. , Nat Commun, 2020, 11: 4287 PMID: 32855419
  6. Yue Sheng, .et al. , Blood, 2020, Aug 21 PMID: 32822452
  7. Hald øH, .et al. , Oncogene, 2018, Dec 12 PMID: 30542116
  8. Louise E. Kerry, .et al. , PLoS Negl Trop Dis, 2017, Mar; 11(3): e0005432 PMID: 28263991

Added to your cart

View Cart Checkout
Loading...